Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 18:13:169-180.
doi: 10.2147/CPAA.S288840. eCollection 2021.

Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor

Nisha S Joseph  1 , Yu-Tzu Tai  2 , Kenneth C Anderson  2 , Sagar Lonial  1
Affiliations
Review

Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor

Nisha S Joseph et al. Clin Pharmacol. .

Abstract

Though survival outcomes in multiple myeloma patients have improved drastically over the past few decades, there still remains an ongoing need for effective and tolerable treatment options in the relapsed and refractory space. Encouragingly, there have been three recent FDA approvals for triple-class refractory multiple myeloma, and there is promising ongoing development of additional agents with varying novel mechanisms of action. Here, we will review the most recent data on both belantamab mafodotin, an antibody drug conjugate (ADC) targeting BCMA, and selinexor, a first-in-class selective inhibitor of XPO1, as well as touch on some of the recently published data for other immunotherapies in development, namely bispecific T cell engagers, ADCs, and CAR-T cell therapies.

Keywords: belamaf; belantamab mafodotin; myeloma; relapsed/refractory myeloma; selinexor.

PubMed Disclaimer

Conflict of interest statement

Dr Kenneth C Anderson reports personal fees from Pfizer, Amgen, AstraZeneca, Janssen, Precision Biosciences, Mana, Windmill, Raqia, C4 Therapeutics, and oncopep, during the conduct of the study. Dr Sagar Lonial reports grants and/or personal fees from Takeda, Janssen, BMS, Celgene, GSK, AbbVie, Bluebird, Novartis, and Pfizer; personal fees from and board of directors for TG Therapeutics, during the conduct of the study. The authors report no other conflicts of interest in this work.

Similar articles

See all similar articles

Cited by

References

    1. Kumar SK, Dimopoulos MA, Kastritis E, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31(11):2443–2448. doi:10.1038/leu.2017.138 - DOI - PubMed
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Populations - Total U.S. (1969-2019), National Cancer Institute, DCCPS, Surveillance Research Program, 2020.
    1. Joseph N, Kaufman J, Dhodapkar M, et al. Long-Term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol. 2020;38:JCO.19.02515. doi:10.1200/JCO.19.02515 - DOI - PMC - PubMed
    1. Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266–2275. doi:10.1038/s41375-019-0435-7 - DOI - PMC - PubMed
    1. Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19(8):2048–2060. doi:10.1158/1078-0432.CCR-12-2422 - DOI - PMC - PubMed